NICE recommends Ajovy for prevention of migraine.- Teva
Related news and insights
Eli Lilly and Company announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the preventive treatment of episodic migraine in adults.
H. Lundbeck A/S announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended granting a marketing authorization to Vyepti (eptinezumab) in the European Union (EU) for the preventive treatment of migraine in adults who have at least 4 migraine days per month.
Amgen announced new data from the HER-MES study, the first and only head-to-head study of Aimovig (erenumab-aooe), a calcitonin gene-related peptide (CGRP) inhibitor, against topiramate for adult patients with episodic and chronic migraine.